Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges

Rhea-AI Filing Summary

Fulgent Genetics, Inc. insider Ming Hsieh filed Amendment No. 5 to update his ownership in the company’s common stock. He beneficially owns 8,872,539 shares, representing 32.26% of the 27,493,435 shares outstanding as of May 22, 2026. The Ming Hsieh Trust beneficially owns 7,895,115 shares, or 28.72% of the class.

Since the prior amendment, Hsieh acquired additional shares solely through vesting of equity awards; on May 26, 2026, 5,496 RSU shares vested, with 2,949 shares withheld for taxes, and no cash consideration was paid. A total of 1,000,000 trust shares are pledged under a pre-paid forward arrangement and 5,760,733 trust shares secure a credit facility, so the lender may dispose of these if there is a default. Hsieh indicates he holds the stake for general investment purposes but may increase or decrease his holdings over time.

Key Figures

Ming Hsieh beneficial ownership: 8,872,539 shares (32.26%) Trust beneficial ownership: 7,895,115 shares (28.72%) Shares outstanding: 27,493,435 shares +5 more

8 metrics

Ming Hsieh beneficial ownership 8,872,539 shares (32.26%) Beneficially owned Fulgent Genetics common stock as of May 22, 2026

Trust beneficial ownership 7,895,115 shares (28.72%) Common stock held by The Ming Hsieh Trust as of May 22, 2026

Shares outstanding 27,493,435 shares Fulgent Genetics common stock issued and outstanding as of May 22, 2026

Recent RSU vesting 5,496 shares Common stock vested from RSUs on May 26, 2026

Shares withheld for taxes 2,949 shares Portion of RSU vesting withheld to pay withholding taxes

Shares pledged to pre-paid forward 1,000,000 shares Trust shares pledged as security under pre-paid forward arrangement

Shares pledged for credit facility 5,760,733 shares Trust shares pledged as collateral for credit facility

Shared voting/dispositive power 221,816 shares Shares over which Ming Hsieh has shared voting and dispositive power

Key Terms

beneficially owns, Restricted Stock Unit, pre-paid forward arrangement, credit facility, +2 more

6 terms

beneficially owns financial

"The Reporting Person beneficially owns 8,872,539 shares of Common Stock of the Issuer"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

Restricted Stock Unit financial

"8,185 shares of Common Stock of the Issuer subject to Restricted Stock Unit awards granted to Mr. Hsieh"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

pre-paid forward arrangement financial

"1,000,000 shares of Common Stock of the Issuer are pledged as security pursuant to a pre-paid forward arrangement"

credit facility financial

"5,760,733 shares of Common Stock are pledged as collateral for a credit facility provided to the Trust"

A credit facility is a flexible loan arrangement that allows a borrower to access funds up to a set limit whenever needed, similar to a company having an overdraft option on a bank account. It matters to investors because it indicates how easily a business can secure cash when required, affecting its ability to manage expenses, invest, or respond to financial challenges.

Dynasty Trust financial

"220,816 shares of Common Stock of the Issuer held by the Dynasty Trust"

Schedule 13D regulatory

"No cash consideration was paid for the acquisition of shares of Common Stock since the filing of Amendment No. 4 to this Schedule 13"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 07:42 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

Fulgent Genetics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

359664109

(CUSIP Number)

Ming Hsieh
c/o Fulgent Genetics, Inc., 4399 Santa Anita Avenue
El Monte, CA, 91731
(626) 350-0537

Scott M. Stanton, Esq.
c/o Mintz, 3580 Carmel Mountain Road, Suite 300
San Diego, CA, 92130
(858) 314-1500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/22/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 359664109

1

Name of reporting person

Ming Hsieh

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 8,650,723.00
8	Shared Voting Power 221,816.00
9	Sole Dispositive Power 8,650,723.00
10	Shared Dispositive Power 221,816.00

11

Aggregate amount beneficially owned by each reporting person

8,872,539.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

32.26 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

In reference to Row 4 above, the shares of common stock, par value $0.0001 per share (the "Common Stock"), of Fulgent Genetics, Inc. (the "Issuer") acquired by Ming Hsieh (the "Reporting Person") since the Reporting Person's last amendment to this Schedule 13D were acquired through equity award vestings in connection with the Reporting Person's services as Chief Executive Officer of the Issuer. No cash consideration was paid by the Reporting Person in connection with these acquisitions. See Item 3 of this Schedule 13D for additional information. In reference to Rows 7 and 9 above, sole voting and dispositive power consists of (i) 7,895,115 shares of Common Stock of the Issuer held of record by The Ming Hsieh Trust (the "Trust"), of which Mr. Hsieh possesses sole voting and dispositive power as the trustee, of which 1,000,000 shares of Common Stock of the Issuer are pledged as security pursuant to a pre-paid forward arrangement as disclosed on that certain Form 4 filed by the Reporting Person with the U.S. Securities and Exchange Commission (the "SEC") on March 12, 2024, and 5,760,733 shares of Common Stock are pledged as collateral account for a credit facility, (ii) 746,423 shares of Common Stock of the Issuer held of record by Mr. Hsieh, (iii) 1,000 shares of Common Stock of the Issuer held of record by a minor child under a Uniform Transfers to Minors Act account, of which Mr. Hsieh possesses sole voting and dispositive power as the sole custodian of the account, and (iv) 8,185 shares of Common Stock of the Issuer subject to Restricted Stock Unit awards granted to Mr. Hsieh that will vest or settle within 60 days after May 27, 2026. This 8,185 shares of Common Stock presumes no shares are withheld for the purposes of withholding taxes. In reference to Rows 8 and 10 above, shared voting and dispositive power consists of (i) 220,816 shares of Common Stock of the Issuer held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, serve on the investment committee of the Dynasty Trust and (ii) 1,000 shares of Common Stock of the Issuer held by an immediate family member of Mr. Hsieh residing in the same household which were previously held in a custodial account under the Uniform Transfers to Minors Act, over which Mr. Hsieh served as sole custodian, and were transferred to this immediate family member upon this individual reaching the age of majority. Mr. Hsieh may be deemed to share voting and dispositive power over these 1,000 shares by virtue of this family member's residence in his household. Mr. Hsieh disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. In reference to Row 13 above, the percent of class represented by amount in Row 11 was calculated based on 27,493,435 shares of Common Stock of the Issuer issued and outstanding as of May 22, 2026, based on information provided to the Reporting Person by the Issuer.

SCHEDULE 13D

CUSIP Number(s): 359664109

1

Name of reporting person

The Ming Hsieh Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,895,115.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 7,895,115.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

7,895,115.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

28.72 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

In reference to Row 4 above, the Trust has not acquired any shares of Common Stock since the Reporting Person's last amendment to this Schedule 13D. All shares of Common Stock currently held by the Trust were acquired through transfers from the Reporting Person as previously reported. See Item 3 of Amendment No. 4 to Schedule 13D previously filed with the SEC on March 31, 2026, for additional information. In reference to Rows 7 and 9 above, sole voting and dispositive power consists of 7,895,115 shares of Common Stock of the Issuer held of record by the Trust, over which the Reporting Person possesses sole voting and dispositive power as the trustee of the Trust. In reference to Row 13 above, the percent of class represented by amount in Row 11 was calculated based on 27,493,435 shares of Common Stock of the Issuer issued and outstanding as of May 22, 2026, based on information provided to the Reporting Person by the Issuer.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: Fulgent Genetics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 4399 Santa Anita Avenue, El Monte, CALIFORNIA , 91731.
Item 1 Comment: This amendment No. 5 to Schedule 13D (this "Statement") relates to the common stock, par value $0.0001 per share (the "Common Stock"), of Fulgent Genetics, Inc., a Delaware corporation (the "Issuer"). The principal executive office of the Issuer is located at 4399 Santa Anita Avenue, El Monte, California 91731. Except as expressly amended herein, this Statement supplements Amendment No. 4 to Schedule 13D previously filed with the SEC on March 31, 2026.
Item 2.	Identity and Background
(a)	This Statement is being filed by Ming Hsieh, (the "Reporting Person") and by the Reporting Person on behalf of The Ming Hsieh Trust (the "Trust").
(b)	The business address of the Reporting Person and the Trust is c/o Fulgent Genetics, Inc., 4399 Santa Anita Avenue, El Monte, California 91731.
(c)	The Reporting Person serves as Chief Executive Officer and Chairperson of the Board of Directors (the "Board") of the Issuer. The Trust was formed for personal estate planning purposes.
(d)	During the last five years, neither the Reporting Person nor the Trust has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, neither the Reporting Person nor the Trust has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	The Reporting Person is a citizen of the United States of America. The Trust is organized in the State of California.
Item 3.	Source and Amount of Funds or Other Consideration
	Since the filing of Amendment No. 4 to this Schedule 13D, the Reporting Person acquired shares of Common Stock solely upon the vesting of equity awards previously granted under the Issuer's equity incentive plans as described below. No cash consideration was paid for the acquisition of shares of Common Stock since the filing of Amendment No. 4 to this Schedule 13. On May 26, 2026, 5,496 shares of Common Stock vested pursuant to issued and outstanding RSUs. 2,949 shares of Common Stock were withheld for the payment of withholding taxes.
Item 4.	Purpose of Transaction
	The Reporting Person holds the shares of Common Stock reported in this Statement for general investment purposes. The Reporting Person may, from time to time, acquire additional, or dispose of, shares of Common Stock or other securities of the Issuer, in the Reporting Person's capacity as Chief Executive Officer and Chairperson of the Board of the Issuer or otherwise, or engage in discussions with the Issuer concerning investments in the Issuer. The Reporting Person intends to review his ownership of Common Stock (including shares of Common Stock held through the Trust) on a continuing basis and, depending upon the price and availability of shares of Common Stock of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Person, general stock market and economic conditions, tax considerations and other factors considered relevant, the Reporting Person may decide at any time to increase or to decrease the size of his holdings of the Issuer's securities or securities derived of, exercisable for or convertible into the Issuer's securities.
Item 5.	Interest in Securities of the Issuer
(a)	The Reporting Person beneficially owns 8,872,539 shares of Common Stock of the Issuer, representing 32.26% of all of the issued and outstanding shares of Common Stock of the Issuer. The Trust beneficially owns 7,895,115 shares of Common Stock of the Issuer, representing 28.72% of all of the issued and outstanding shares of Common Stock of the Issuer. The percentages set forth in this Item 5(a) are based on 27,493,435 shares of Common Stock issued and outstanding as of May 22, 2026, based on information provided to the Reporting Person by the Issuer.
(b)	The Reporting Person has the sole power to vote or direct the vote and dispose or direct the disposition of 8,650,723 shares of Common Stock of the Issuer (which includes the shares of Common Stock held by the Trust) as of and within sixty (60) days after May 27, 2026. The Reporting Person has shared power to vote or direct the vote or dispose or direct the disposition of 221,816 shares of Common Stock as of and within 60 days of May 27, 2026. The Reporting Person is a member of the investment committee of the Dynasty Trust and, as such, shares voting and dispositive power over the shares held by the Dynasty Trust.
(c)	The transactions effected by the Reporting Person in the 60 days prior to the filing of this Statement are set forth in Item 3 of this Statement. Except as set forth in Item 3 of this Statement, no other transactions in the shares of Common Stock of the Issuer have been effected by the Reporting Person during the 60-day period prior to the filing of this Statement.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	1,000,000 shares of Common Stock of the Trust are pledged as security pursuant to a pre-paid forward arrangement as disclosed on that certain Form 4 filed by the Reporting Person with the SEC on March 12, 2024, and 5,760,733 shares of Common Stock of the Trust are pledged as collateral for a credit facility provided to the Trust by The Charles Schwab Corporation. This arrangement is subject to customary terms which provide that, in the event of a default, the lender may be entitled to dispose of the pledged shares. The Reporting Person and his spouse, Eva Hsieh, are members of the investment committee of the Dynasty Trust. See Item 5(b) of this Statement. Except as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 of this Statement and between such persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1: Joint Filing Agreement, dated as of December 22, 2020, by and among Mr. Hsieh and the Trust (incorporated by reference to Exhibit 1 of that certain Schedule 13D/A filed with the SEC on December 22, 2020). https://www.sec.gov/Archives/edgar/data/1674930/000156459020058063/none-sc13d.htm

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ming Hsieh

Signature:	/s/ Ming Hsieh
Name/Title:	Ming Hsieh
Date:	05/27/2026

The Ming Hsieh Trust

Signature:	/s/ Ming Hsieh
Name/Title:	By: Ming Hsieh, Trustee
Date:	05/27/2026